Hypermarcas (OTCMKTS:HYPMY) Stock Short Interest Report for September

Posted by George Bondi on Oct 15th, 2026

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 4,266 shares, an increase of 82.1% from the September 15th total of 2,343 shares. Based on an average daily volume of 20,164 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short.

Hypermarcas Trading Down 1.3%

Shares of Hypermarcas stock opened at $5.10 on Thursday. The company’s fifty day simple moving average is $4.53 and its 200-day simple moving average is $4.39. The company has a market cap of $3.59 billion, a price-to-earnings ratio of 10.20 and a beta of 0.65. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. Hypermarcas has a 1 year low of $3.72 and a 1 year high of $5.77.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. As a group, sell-side analysts expect that Hypermarcas will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Hypermarcas currently has an average rating of “Buy”.

View Our Latest Research Report on HYPMY

About Hypermarcas

(Get Free Report)

Hypermarcas SA was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera SA, adopting the Hypera Pharma identity.